Abstract 387P
Background
The prevalence of tobacco use has significant implications for the global economy, since it is the leading cause of death and disease worldwide. Currently, tobacco-related factors contribute to an estimated 8 million deaths annually, with a majority of these fatalities concentrated in low- and middle-income countries. The objective of this study was to perform a thorough evaluation of existing literature concerning tobacco use and cancer prevalence across Indian tribal tribes, with the aim of ascertaining the prevalence, distribution, and factors that contribute to tobacco use, which is necessary for the purpose of developing and modifying control strategies aimed at mitigating tobacco consumption among this marginalized community.
Methods
A systematic review was undertaken to examine the available evidence on the oral health status, tobacco use, and cancer prevalence among tribal groups in India. The review was registered in the PROSPERO database. Sources published from 1980 to 2023 from reputable databases like PubMed, Crossref, Google Scholar, and Web of Science were used in this evaluation.
Results
The findings of this study encompass a comprehensive analysis of 22 distinct tribal population involving 28,572 individuals. The prevalence of tobacco consumption varied between 12% and 42.5%. In the context of gender-specific studies, the prevalence of tobacco use among females varied between 1.2% and 12%, whereas among males it ranged from 15% to 52%. The prevalence of oral cancer in this marginalized community ranged from 5% to 12%, as assessed. In contrast, the consumption of smokeless tobacco was prevalent throughout the indigenous community. The primary risk factors for tobacco use were identified as a dearth of information regarding oral health, deeply entrenched dental attitudes, and limited accessibility to health services.
Conclusions
To effectively address the issue of tobacco use, it is imperative to prioritize additional research on improved methodologies, evidence-based policies, and viable options for tobacco cessation. This review recommends implementing campaigns and abstinence as an effective strategy for mitigating the adverse consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract